Table 5.
Vaccine | Vector | Dosage | Price | Vaccination ages |
Immune response |
Protection | Ref. |
---|---|---|---|---|---|---|---|
Leucogen (Virbac, France) |
p45 envelope antigen with adjuvant (aluminium hydroxide gel, extract of Quillaja saponaria) |
Two initial doses at 3–4-week intervals injected im., annual revaccination with single dose |
US$99.99/ten doses (US$9.99/dose) |
8 weeks | Neutralizing antibodies within 9 weeks |
80% preventable fraction against persistent viremia |
[88] |
Purevax®/ Eurifel (Merial Animal Health Ltd, UK) |
Canarypox virus with env and gag genes and part of the pol gene of subgroup A (no adjuvant) |
Two initial doses of 0.25 ml 3–4 weeks apart sc., annual revaccination with single dose |
US$121.99/25 doses (US$4.88/ dose) |
8 weeks | Cytotoxic T-cell response, very limited neutralizing antibody production |
78% preventable fraction for persistent viremia |
[89] |
Leukocell 2 (Pfizer, NY, USA) |
Inactivated, adjuvanted, mixed subunits from FeLV strains A, B and C, with sterile adjuvant |
Two initial doses of 1 ml 3–4 weeks apart sc., annual revaccination with single dose |
US$50.70/ten doses (US$5.07/dose) |
9 weeks | Neutralizing antibodies within 7 weeks |
Protects more than 70% of artificially immunosuppressed cats against persistent viremia |
[90] |
Fel-O-Vax LvK (Fort Dodge, KS, USA) |
Inactivated whole virus of subgroups A and B with adjuvant |
Two initial doses of 1 ml 3–4 weeks apart sc. or im., annual revaccination with single dose |
US$74.00/ten doses (US$7.40/dose) |
9 weeks | Neutralizing antibodies within 11 weeks |
44–100% preventable fraction |
|
Fevaxyn (Schering- Plough, NJ, USA) |
Inactivated whole virus of subgroups A and B with adjuvant |
Two initial doses of 1 ml 3–4 weeks apart sc., annual revaccination with single dose |
US$119.99/25 doses (US$4.80/ dose) |
9 weeks | Unknown | 90.4–100% preventable fraction |
|
DNA vaccine (Hanlon et al. 2001) |
Two plasmids expressing gag/pol and env gene with adjuvant plasmids encoding feline IL-12, IL-18 and/or IFN-γ |
100 µg of each DNA construct injected im. |
Unknown | 13–15 weeks | Unknown | 100% protection against transient and persistent viremia, 5/6 kittens protected against latent infection |
[18] |
FeLV: Feline leukemia virus; im.: Intramuscular; sc.: Subcutaneous.